Current issues of ACP Journal Club are published in Annals of Internal Medicine


The recurrence rate of venous thromboembolism after a first or second episode of deep venous thrombosis was high


ACP J Club. 2000 Nov-Dec;133:117. doi:10.7326/ACPJC-2000-133-3-117

Source Citation

Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Incidence and risk factors. Arch Intern Med. 2000 Mar 27;160:769-74. [PubMed ID: 10737276]



For patients who had a first or second episode of confirmed arm or leg deep venous thrombosis (DVT), what is the incidence of recurrent venous thromboembolism (VTE) (DVT or pulmonary embolism [PE]), and what are the risk factors for recurrence?


Cohort study with 3.7 to 8.8 years of follow-up.


A university hospital in Göteborg, Sweden.


738 patients with DVT confirmed by phlebography or color duplex ultrasonography who had been discharged from the hospital and survived to 1 month. 591 patients (mean age 66 y, 53% women) had a first DVT, and 147 patients had previous VTEs (108 patients with a previous DVT, 19 with a previous PE, and 20 with both DVT and PE). Follow-up for mortality was > 99%.

Assessment of prognostic factors

Data on prognostic factors were collected and used in multivariate analyses: age, sex, duration of oral anticoagulant therapy, location of DVT (arm or leg), level of DVT in leg (distal or proximal), initial antithrombotic treatment, history of VTE, surgery within the past 3 months, immobilization within 1 week of index DVT, and cancer.

Main outcome measures

Recurrent fatal and nonfatal VTE.

Main results

During follow-up, of the 591 patients in the group who had had a first DVT, 109 (18%) had a recurrent VTE (84 DVTs, 14 non-fatal PEs, and 13 fatal PEs). The mortality rate was 42% overall. Of the 136 patients who had had 1 previous VTE, 37 (27%) had a recurrent VTE (26 DVTs, 9 nonfatal PEs, and 2 fatal PEs). Cumulative incidences for both groups are in the Table. Multivariate analysis showed that 3 factors increased the risk for recurrent VTE: proximal DVT as an index event (relative risk [RR] 2.30, 95% CI 1.55 to 3.42); cancer (RR 2.21, CI 1.43 to 3.41); and history of VTE (RR 1.71, CI 1.16 to 2.52). 2 factors decreased the risk for recurrent VTE: DVT after surgery (RR 0.27, CI 0.13 to 0.55) and long-term anticoagulant therapy (RR 0.95, CI 0.92 to 0.98).


The recurrence rate of venous thromboembolism was high. The risk for recurrence was increased if the index event was a proximal deep venous thrombosis, if the patient had a history of venous thromboembolism or cancer but not recent surgery, or if the duration of the initial anticoagulant therapy period had been short.

Sources of funding: Swedish Medical Research Council; King Gustav V and Queen Victoria Foundation; Göteborg Medical Association; Göteborg University.

For correspondence: Dr. P.O. Hansson, Department of Medicine, Sahlgrenska University Hospital-Östra, SE-41685 Göteborg, Sweden. FAX 46-31-3388694.

Table. Cumulative incidence of recurrence of venous thromboembolism after a first or second episode of deep venous thrombosis (DVT)

Time period After first DVT (95% CI) After second DVT (CI)
1 y 7.0% (4.8 to 9.1) 7.6% (3.1 to 12)
2 y 12% (9.3 to 15) 16% (9.3 to 22)
3 y 15% (12 to 18) 19% (12 to 26)
4 y 18% (14 to 21) 26% (18 to 34)
5 y 22% (18 to 25) 28% (20 to 36)


Hansson and colleagues have shown that rates of recurrent VTE remain high despite the standard clinical practice of 3 months of prophylactic oral anticoagulation. Kearon and colleagues (1) eloquently showed that after an initial episode of idiopathic VTE the rate of recurrence was 27.4%/patient-year with placebo and 1.3%/patient-year with continued warfarin. Schulman and colleagues (2) found that prophylactic oral anticoagulation after initial VTE for 6 months rather than 6 weeks reduced recurrence rates. Furthermore, long-term prophylaxis after a second VTE resulted in lower recurrence rates than did 6 months of prophylaxis, although with more major bleeding (3).

These studies provide compelling evidence that VTE should be viewed as a “chronic polygenic disorder” (4) with acute exacerbations and that extended prophylactic anticoagulation in patients with idiopathic VTE and VTE associated with persistent risk factors for thrombosis needs to be strongly considered. Hansson and colleagues did not present data on the presence of factor V Leiden, 1 of the most common inherited hypercoagulable states associated with recurrent VTE (5). It is unclear whether long-term prophylaxis in patients with factor V Leiden who have an initial VTE is warranted, considering that the risk for anticoagulant-related bleeding is directly associated with the duration of therapy (6). The results of an ongoing trial to assess the efficacy of extended low-dose warfarin in the secondary prevention of VTE among patients with and without factor V Leiden will, I hope, provide much-needed answers (7).

Rebecca J. Beyth, MD, MS
Baylor College of Medicine
Houston, Texas, USA


1. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7.

2. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332: 1661-5.

3. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336: 393-8.

4. Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med. 1999;340:955-6.

5. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506—Gln mutation in the gene for factor V. N Engl J Med. 1997;336: 399-403.

6. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998;114: 511S-23S.

7. Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial. Vasc Med. 1998;3:67-73.